Peer-Spectives Oncololgy News Central

From ASCO 2024, Dr. Robert Figlin speaks with Dr. Samer Al Hadadi from University of Arkansas.
"Very Important" Myeloma Data: ASCO Highlights, Smoldering Challenges, and More.

From ASCO 2024, Dr. Robert Figlin talks with Dr. Lauren Averett Byers from MD Anderson Cancer Center.
Durvalumab's Benefit in SCLC "Beyond What We Might Have Expected"

From ASCO 2024
New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers "Fantastic" Potential, Expert Says.
Dr. Robert Figlin speaks with Dr. Christian Blank from Leiden University

From ASCO 2024, Dr. Robert Figlin welcomes Dr. Aditya Bardia from UCLA Health Jonsson Comprehensive Cancer Center.
Should All Breast Cancer Patients Get T-DXd? "Results of DESTINY-Breast06 Do Suggest That"

Especially in rural areas, the growing oncologist shortage has “gotten to crisis level,” says Harsha Vyas, MD, president and founding partner of Cancer Center of Middle Georgia in Dublin. “We just don’t have enough supply of medical oncologists/hematologists,” he tells Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. Dr. Vyas puts forth his ideas for potential solutions, ranging from medical school debt repayment to congressional intervention. As Dr. Figlin notes, “we need to rethink” current approaches because there’s a “storm” on the horizon and “we’re all seeing it coming.”
Dr. Vyas reported no relevant financial relationships.
Dr. Figlin reported various financial relationships.

The development of noncovalent Bruton tyrosine kinase (BTK) inhibitors and other advances in chronic lymphocytic leukemia treatment signify that the “future is really exciting,” says Jennifer A. Woyach, MD, professor in the Division of Hematology at The Ohio State University in Columbus. Dr. Woyach speaks with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, about the potential of moving these new drugs into the frontline setting and other questions related to BTK inhibitor resistance.

Dr. Woyach reported various financial relationships.
Dr. Figlin reported various financial relationships.